Palo Alto, California-based Simplee, which provides a payment platform for healthcare patients, has raised $20 million in a Series C funding round led by existing investor Social Capital. Also participating are existing investors 83North, Heritage Group and new investor American Express Ventures. The company raised $16 million in its two previous rounds combined, including a $10 million Series B in September 2013.
3 min read · 10 May 2016
Farmington, Conn.-based Evariant, a provider of a healthcare-focused CRM platform, announced it has raised additional funding from McKesson Ventures and Salesforce Ventures as part of its Series C round of funding. They join existing investors Health Enterprise Partners, Lightspeed Venture Partners and Goldman, Sachs & Co. Evariant announced in December it raised a $42.3 million Series C round of funding, bringing its total funding amount to $66 million at the time.
3 min read · 10 May 2016
Farmington, Conn.-based Evariant, a provider of a healthcare-focused CRM platform, announced it has raised additional funding from McKesson Ventures and Salesforce Ventures as part of its Series C round of funding. They join existing investors Health Enterprise Partners, Lightspeed Venture Partners and Goldman, Sachs & Co. Evariant announced in December it raised a $42.3 million Series C round of funding, bringing its total funding amount to $66 million at the time.
3 min read · 10 May 2016
San Francisco-based Next World Capital has raised $122.75 million for its second fund, which is targeted at $125 million, according to a regulatory filing. The commitments were raised from 11 investors.
1 min read · 10 May 2016
Palo Alto, California-based Vera announced that Mark Leslie, founder, chairman and former CEO of Veritas Software, will join the company board. The appointment comes as Vera also announced that it recently closed a strategic investment from Capital One Growth Ventures to its oversubscribed Series B funding round. Vera, formerly known as Veradocs, had previously announced a $17 million funding round in February led by Sutter Hill Ventures, with participation from existing investors Battery Ventures and Amplify Partners. The company, which provides solutions for businesses to secure, track and share digital information across platforms and devices, has now raised $35 million in total funding.
3 min read · 10 May 2016
Palo Alto, California-based Vera announced that Mark Leslie, founder, chairman and former CEO of Veritas Software, will join the company board. The appointment comes as Vera also announced that it recently closed a strategic investment from Capital One Growth Ventures to its oversubscribed Series B funding round. Vera, formerly known as Veradocs, had previously announced a $17 million funding round in February led by Sutter Hill Ventures, with participation from existing investors Battery Ventures and Amplify Partners. The company, which provides solutions for businesses to secure, track and share digital information across platforms and devices, has now raised $35 million in total funding.
3 min read · 10 May 2016
White Plains, N.Y.-based Rethink Education has raised $67.175 million toward a $125 million targeted second fund, according to a regulatory filing. The filing indicates the firm has raised the commitments from 44 investors. Rethink raised $25 million for its first fund, which closed in 2012, according to Thomson Reuters.
1 min read · 09 May 2016
White Plains, N.Y.-based Rethink Education has raised $67.175 million toward a $125 million targeted second fund, according to a regulatory filing. The filing indicates the firm has raised the commitments from 44 investors. Rethink raised $25 million for its first fund, which closed in 2012, according to Thomson Reuters.
1 min read · 09 May 2016
A roundup of firms that have filed their intent to raise new funds or they have reported initial closes
3 min read · 09 May 2016
San Francisco-based venBio Partners announced it has raised $315 million for its second life science fund, which is anchored by investments from strategic LPs Amgen, Merck and Baxalta. The amount exceeds the $250 million target it set in March 2015, according to a regulatory filing. The firm, which also has an office in New York, typically invests in clinical-stage life science companies with a therapeutic product.
3 min read · 06 May 2016
